EA201890400A1 - Способы и композиции для иммунной защиты против внекишечной патогенной e. coli - Google Patents

Способы и композиции для иммунной защиты против внекишечной патогенной e. coli

Info

Publication number
EA201890400A1
EA201890400A1 EA201890400A EA201890400A EA201890400A1 EA 201890400 A1 EA201890400 A1 EA 201890400A1 EA 201890400 A EA201890400 A EA 201890400A EA 201890400 A EA201890400 A EA 201890400A EA 201890400 A1 EA201890400 A1 EA 201890400A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
coli
expec
protection against
Prior art date
Application number
EA201890400A
Other languages
English (en)
Other versions
EA037500B1 (ru
Inventor
Ян Тёнис Пулман
Берт Жакмин
Даррен Роберт Эббэнэт
Патрисия Ибарра Ён
Петер Вилхелмус Мария Германс
Михель Томас Коварик
Михель Лукас Веттер
Стэфан Йохан Кеммлер
Миха Андрес Хауптле
Вероника Гамбиллара
Мануэла Малли
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Янссен Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А., Янссен Фармасьютикалз, Инк. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201890400A1 publication Critical patent/EA201890400A1/ru
Publication of EA037500B1 publication Critical patent/EA037500B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Описаны композиции и способы для индукции иммунного ответа против внекишечной патогенной Escherichia coli (ExPEC), за счет этого обеспечивая иммунную защиту против заболеваний, ассоциированных с ExPEC. В частности, описаны композиции и способы применения конъюгатов антигенов полисахаридов E. coli O25B, O1A, O2 и O6A, ковалентно связанных с белком-носителем, обезвреженным экзотоксином A Pseudomonas aeruginosa (EPA), в качестве вакцин для предупреждения инвазивного заболевания ExPEC, вызванного ExPEC серотипов O1A, O2, O6A и O25B.
EA201890400A 2015-08-24 2016-08-24 Способы и композиции для иммунной защиты против внекишечной патогенной e. coli EA037500B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209091P 2015-08-24 2015-08-24
US201562210655P 2015-08-27 2015-08-27
PCT/US2016/048278 WO2017035181A1 (en) 2015-08-24 2016-08-24 Methods and compositions for immune protection against extra-intestinal pathogenic e. coli

Publications (2)

Publication Number Publication Date
EA201890400A1 true EA201890400A1 (ru) 2018-09-28
EA037500B1 EA037500B1 (ru) 2021-04-05

Family

ID=56855827

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890400A EA037500B1 (ru) 2015-08-24 2016-08-24 Способы и композиции для иммунной защиты против внекишечной патогенной e. coli

Country Status (19)

Country Link
US (3) US10583185B2 (ru)
EP (2) EP4245320A3 (ru)
JP (1) JP6872532B2 (ru)
KR (1) KR20180054629A (ru)
CN (1) CN108430500B (ru)
AU (1) AU2016312422B2 (ru)
BR (1) BR112018003469A2 (ru)
CA (1) CA2995873A1 (ru)
EA (1) EA037500B1 (ru)
ES (1) ES2951408T3 (ru)
HR (1) HRP20230947T1 (ru)
HU (1) HUE063961T2 (ru)
IL (1) IL257608B (ru)
MX (1) MX2018002340A (ru)
NZ (1) NZ739963A (ru)
PL (1) PL3341016T3 (ru)
RS (1) RS64449B1 (ru)
TW (1) TWI715617B (ru)
WO (1) WO2017035181A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
WO2014111516A1 (en) 2013-01-17 2014-07-24 Arsanis Biosciences Gmbh Mdr e. coli specific antibody
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AR118389A1 (es) 2019-03-18 2021-09-29 Janssen Pharmaceuticals Inc Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
CN115485550A (zh) 2020-04-28 2022-12-16 杨森制药公司 用于鉴定和定量复合糖缀合物组合物中的多糖的方法
JP2023531059A (ja) 2020-06-25 2023-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎桿菌ｏ抗原ワクチン
IL301248B2 (en) 2020-09-17 2024-04-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and their uses
CA3203450A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceuticals, Inc. Analytical method for glycoconjugates using a capillary-based immunoassay system
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
WO2022178020A1 (en) 2021-02-16 2022-08-25 Duke University Vaccine compositions and methods for the treatment and prevention of urinary tract infections
CA3215752A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
CN117098550A (zh) 2021-04-08 2023-11-21 杨森制药公司 生物缀合物生产方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US20050287628A1 (en) 2002-03-07 2005-12-29 Markus Aebi System and method for the production of recombinant glycosylated proteins in a prokaryotic host
BRPI0510882A (pt) * 2004-05-14 2007-12-26 Ca Nat Research Council epìtopes lipopolisacarìdeos de núcleo interno conservado como candidatos de espécie de vacina: epìtopes lipopolisacarìdeos de núcleo interno como candidatos de vacina para a prevenção de doenças causadas por patogêneses bacterianas veterinárias incluindo actinobacillus pleuropneumoniae, mannheimia haemolytica e pasteurella multocida
AU2006245969B8 (en) 2005-05-11 2011-08-25 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
US8895014B2 (en) * 2008-02-20 2014-11-25 Glycovaxyn Ag Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
AU2010322454B2 (en) 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
CA2819366A1 (en) 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
AU2012306345A1 (en) 2011-09-06 2014-03-20 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
AU2013311534A1 (en) * 2012-09-10 2015-03-12 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
EA201590488A1 (ru) 2012-10-12 2015-09-30 Гликоваксин Аг Способы модификации клеток-хозяев
WO2014102265A1 (en) 2012-12-27 2014-07-03 Glycovaxyn Ag Methods and compositions relating to crm197
WO2014111516A1 (en) * 2013-01-17 2014-07-24 Arsanis Biosciences Gmbh Mdr e. coli specific antibody
ES2778074T3 (es) 2013-10-11 2020-08-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP3102599B1 (en) 2014-02-06 2019-02-27 ARSANIS Biosciences GmbH E. coli specific antibody sequences
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
PT3240895T (pt) 2014-12-30 2022-03-02 Glaxosmithkline Biologicals Sa Composições e métodos para glicosilação de proteínas
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec

Also Published As

Publication number Publication date
JP6872532B2 (ja) 2021-05-19
TWI715617B (zh) 2021-01-11
HRP20230947T1 (hr) 2023-11-24
EA037500B1 (ru) 2021-04-05
JP2018525423A (ja) 2018-09-06
IL257608A (en) 2018-04-30
CA2995873A1 (en) 2017-03-02
NZ739963A (en) 2024-02-23
WO2017035181A1 (en) 2017-03-02
EP3341016B1 (en) 2023-06-07
PL3341016T3 (pl) 2023-11-13
CN108430500A (zh) 2018-08-21
US20230062987A1 (en) 2023-03-02
MX2018002340A (es) 2018-09-17
HUE063961T2 (hu) 2024-02-28
RS64449B1 (sr) 2023-09-29
EP4245320A2 (en) 2023-09-20
US11484582B2 (en) 2022-11-01
EP3341016C0 (en) 2023-06-07
KR20180054629A (ko) 2018-05-24
US20210046171A1 (en) 2021-02-18
CN108430500B (zh) 2021-12-24
AU2016312422A1 (en) 2018-03-29
BR112018003469A2 (pt) 2018-09-25
US20180243393A1 (en) 2018-08-30
EP3341016A1 (en) 2018-07-04
US10583185B2 (en) 2020-03-10
IL257608B (en) 2021-12-01
EP3341016B9 (en) 2023-09-27
TW201714620A (zh) 2017-05-01
EP4245320A3 (en) 2023-11-22
AU2016312422B2 (en) 2019-09-26
ES2951408T3 (es) 2023-10-20

Similar Documents

Publication Publication Date Title
EA201890400A1 (ru) Способы и композиции для иммунной защиты против внекишечной патогенной e. coli
PH12019500561A1 (en) Expec glycoconjugate vaccine formulations
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
EA201691478A1 (ru) Новый полисахарид и его применения
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
MX2023012389A (es) Vacuna.
EP4286000A3 (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
WO2015175355A8 (en) Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates
WO2020039359A3 (en) Escherichia coli compositions and methods thereof
CY1121083T1 (el) Αντιμικροβιακο πεπτιδιο και οι χρησεις αυτου
EA201990451A1 (ru) Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение
MX2023003169A (es) Composiciones de vacunas multivalentes y usos de las mismas.
ZA201902696B (en) Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4- acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
WO2019126341A3 (en) Compositions and methods for the treatment of bacterial infections
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
AR105793A1 (es) Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal
EP2566508A4 (en) POLYSACCHARIDE CONJUGATES USED AS VACCINES WITH DETOXIFIED HEATING ELEMENT E. COLI-ENTEROTOXIN (LT)
AR125423A1 (es) Vacunas contra infecciones del tracto urinario
Saidi et al. The effect of probiotic yeast Saccharomyces cerevisiae on Staphylococcus aureus biofilm
MX2019015698A (es) Vacuna de subunidades anti-mycoplasma spp.
MX2019015697A (es) Vacuna de subunidades anti-mycoplasma spp.